UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib

被引：1
|
作者：
Miura, S. [1 ]
Maerten, A. [2 ]
Popat, S. [3 ,4 ]
机构：
[1] Niigata Univ, Dept Homeostat Regulat & Dev, Div Resp Med, Niigata, Japan
[2] Boehringer Ingelheim Int GmbH, Dept Med, Ingelheim, Germany
[3] Royal Marsden Natl Hlth Serv Fdn Trust, Lung Unit, London, England
[4] Inst Canc Res, London, England
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.466
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
420TiP
引用
收藏
页码：S1405 / S1406
页数：2
相关论文
共 50 条
  • [41] Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
    Gottfried, M.
    de Marinis, F.
    Tu, H.
    Laktionov, K. K.
    Feng, J.
    Poltoratskiy, A.
    Zhao, J.
    Tan, E-H.
    Lee, V.
    Kowalski, D.
    Yang, C-T.
    Srinivasa, B.
    Passaro, A.
    Clementi, L.
    Tang, W.
    Huang, D. C-L.
    Cseh, A.
    Park, K.
    Zhou, C.
    Wu, Y-L.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [42] A phase IIIb open-label study of afatinib in EGFR TKI-naive patients (pts) with EGFR mutation-positive (EGFRm1) NSCLC: Exploratory biomarker analysis
    Wang, J.
    Zhao, J.
    Bai, H.
    Wang, X.
    Wang, Y.
    Duan, J.
    Chen, H.
    Meng, S.
    Tian, Y.
    Huang, D. C-L.
    Wu, Y-L.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [43] Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)
    Halmos, Balazs
    Tan, Eng-Huat
    Soo, Ross A.
    Cadranel, Jacques
    Lee, Min Ki
    Foucher, Pascal
    Hsia, Te-Chun
    Hochmair, Maximilian
    Griesinger, Frank
    Hida, Toyoaki
    Kim, Edward
    Melosky, Barbara
    Maerten, Angela
    Carcereny, Enric
    [J]. LUNG CANCER, 2019, 127 : 103 - 111
  • [44] Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
    Miura, Satoru
    Hsia, Te-Chun
    Hung, Jen-Yu
    Jung, Hyun Ae
    Shih, Jin-Yuan
    Park, Cheol-Kyu
    Lee, Seung Hyeun
    Okamoto, Tatsuro
    Ahn, Hee Kyung
    Lee, Yong Chul
    Sato, Yuki
    Lee, Sung Sook
    Mascaux, Celine
    Daoud, Hasan
    Maerten, Angela
    Popat, Sanjay
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Real-World Data of Osimertinib in Patients with Metastatic EGFRm plus NSCLC who Progressed on First-Line EGFR TKIs
    Ma, J.
    Tan, S. H.
    Yin, D.
    Tran, A.
    Tan, D.
    Ang, M.
    Takano, A.
    Lim, K. H. T.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Tan, E.
    Lim, D. W.
    Ng, Q. S.
    Tan, W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S627 - S628
  • [46] Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis
    Feinberg, Bruce
    Halmos, Balazs
    Gucalp, Rasim
    Tang, Wenbo
    Moehring, Barbara
    Hochmair, Maximillian J.
    [J]. FUTURE ONCOLOGY, 2020, 16 (22) : 1585 - 1595
  • [47] Subsequent Therapies Post-Afatinib Among Patients with EGFR Mutation-Positive (EGFRm plus ) NSCLC in LUX-Lung 3, 6 and 7
    Sequist, L. V.
    Wu, Y.
    Schuler, M.
    Kato, T.
    Yang, J. C.
    Tanaka, H.
    Hida, T.
    Lu, S.
    Park, K.
    Paz-Ares, L.
    Laurie, S.
    Bennouna, J.
    Sibilot, D. Moro
    Maerten, A.
    Tang, W.
    Ehrnrooth, E.
    Yamamoto, N.
    Nakagawa, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1572 - S1572
  • [48] A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naive Patients with EGFR Mutation-Positive NSCLC: Final Analysis
    Wu, Y.
    Tu, H.
    Feng, J.
    Shi, M.
    Zhao, J.
    Wang, Y.
    Chang, J.
    Wang, J.
    Cheng, Y.
    Zhu, J.
    Tan, E.
    Zhang, Y.
    Lee, V.
    Yang, C.
    Su, W.
    Lam, D. C.
    Srinivasa, B.
    Rajappa, S.
    Ho, C.
    Lam, K. C.
    Hu, Y.
    Bondarde, S. A.
    Liu, X.
    Pang, K.
    Tian, Y.
    Cseh, A.
    Huang, D. C.
    Zhou, C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S679 - S680
  • [49] A phase IIIb, open-label study of afatinib in EGFR TKI-naive patients with EGFR mutation-positive NSCLC: A biomarker analysis
    Rosell, R.
    Poltoratskiy, A.
    Hochmair, M.
    Laktionov, K. K.
    Ramlau, R.
    Alonso Garcia, M.
    Skrickova, J.
    Piovano, P. L.
    Rizzato, S.
    Bidoli, P.
    Kowalski, D.
    Clementi, L.
    Cseh, A.
    De Marinis, F.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [50] Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
    Kenichi Koyama
    Satoru Miura
    Satoshi Watanabe
    Satoshi Shoji
    Jun Koshio
    Yoshiki Hayashi
    Daisuke Ishikawa
    Ko Sato
    Takao Miyabayashi
    Masaaki Okajima
    Takeshi Ota
    Tomohiro Tanaka
    Naoya Matsumoto
    Hideyuki Kuriyama
    Tetsuya Abe
    Koichiro Nozaki
    Kosuke Ichikawa
    Rie Kondo
    Hiroshi Tanaka
    Toshiaki Kikuchi
    [J]. Scientific Reports, 12
12345